[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.197.90.95. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Medical News and Perspectives
December 1, 2010

As Trials Advance for a Malaria Vaccine, Policy Makers Urged to Plan for Its Use

JAMA. 2010;304(21):2348. doi:10.1001/jama.304.21.2348

As the first promising malaria vaccine makes its way through phase 3 clinical trials in sub-Saharan Africa, stakeholders' greatest fears go beyond the possibility that the vaccine may fail to meet safety and efficacy goals. They worry that even if the vaccine is licensed, inadequate planning for its distribution could leave it to languish in warehouses.

“After decades of research and tens of millions of dollars invested  . . .  it would be scandalous if this vaccine just sits on the shelf,” said Yvette Collymore, MA, of the nonprofit PATH Malaria Vaccine Initiative (MVI), during a recent Washington, DC, conference.

First Page Preview View Large
First page PDF preview
First page PDF preview
×